Stock data
ArriVent BioPharma, Inc. (AVBP)
ArriVent BioPharma, Inc. (AVBP) reported net income of -US$166.31M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$177.53M | -US$166.31M | — |
| 2024 | — | — | -US$94.31M | -US$80.49M | — |
| 2023 | — | — | -US$74.59M | -US$69.33M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$49.89M | — |
| 2026-03-31 | — | -US$43.32M | — |
| 2025-12-31 | — | -US$35.54M | — |
| 2025-09-30 | — | -US$34.98M | — |
| 2025-06-30 | — | -US$31.40M | — |
| 2025-03-31 | — | -US$64.39M | — |
| 2024-12-31 | — | -US$20.63M | — |
| 2024-09-30 | — | -US$20.56M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.